WASHINGTON, Dec 23 (Reuters) - Haemonetics Corp has failed to correct a variety of manufacturing issues, including taking proper steps to ensure the quality of its blood collection products, the U.S. Food and Drug Administration warned in a letter released on Tuesday.
